INOVIO Pharmaceuticals

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO), a biotechnology company, announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) …

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023 Read More